GW Pharma High On Epilepsy Results, Plans 2017 NDA
The biotech announces another set of positive anti-seizure results for its marijuana-derived product.
You may also be interested in...
Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.